Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
Would you continue to monitor urinary protein levels and dose adjust axitinib in a patient with metastatic malignancy who is now dialysis dependent but has residual renal function?
Related Questions
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
Do you recommend holding ACE inhibitors, ARBs, and SGLT2 inhibitors for patients with chronic kidney disease and malignancy who are about to start high-dose intravenous methotrexate?
Do you avoid performing urine microscopy in patients with AKI who have COVID-19 given concern for potential aerosolization?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How would you approach management of a patient with ESRD on the transplant list who is found to have high titer APS labs (ACL, B2GP1, LAC)?
How do you work up and manage an ESKD patient with controlled blood pressure who complains of recurrent headaches while on hemodialysis?
How often do you check renal function panels for patients with recurrent nephrolithiasis?
Do you have a preference between midodrine and droxidopa for patients with ESKD who experience intradialytic hypotension?
Do you offer home administration of ESAs for your patients with anemia of chronic kidney disease?
Do you wait until serum anti-GBM antibody titers are undetectable before hospital discharge in a patient with anti-GBM antibody disease with renal involvement who is receiving daily plasmapheresis, cyclophosphamide, and steroids?
